Tag Archives: MEK inhibitor

December, 2017

  • 20 December

    Array BioPharma and Pfizer Collaborate on Novel Anti-Cancer Combinations

    BOULDER, Colo., Dec. 19, 2017 /PRNewswire/ — Array BioPharma (Nasdaq: ARRY) announced today that it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel anti-cancer combinations, including Array’s MEK inhibitor, binimetinib, with Pfizer’s investigational PARP inhibitor talazoparib, and avelumab*, a …

May, 2017

August, 2016

  • 9 August

    AstraZeneca’s NSCLC Candidate Fails in Late-Stage Trial

    AstraZeneca today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). The results showed that the trial did not meet its primary endpoint …

May, 2016

October, 2015

  • 6 October

    Exelixis Announces Positive Results for its Late-Stage Melanoma Trial

    SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Oct. 6, 2015– Exelixis, Inc.(NASDAQ:EXEL) today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 …